Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Dr Paul Overton

Paul joined Sygnature Discovery in June 2020 as Chief Commercial Officer and Executive Board Director.

He has over 20 years of business development experience in the pharmaceutical and biotechnology sectors delivering integrated development solutions. Paul has previously held roles in Eurofins BPT as Head of Europeans Sales, in Evotec as Global Head Business Development and in Aptuit as EVP Global Business and Corporate Development. After initially working in the research developing diagnostic assays and bioanalytical methods, he transitioned into a commercial career in the preclinical development space.

Paul has a degree in Applied Biological Sciences from Bristol and  a PhD in cellular immunology from Surrey University.